NYSEAMERICAN:PFNX - Pfenex Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.00
  • Forecasted Upside: 1.96 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$12.75
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Pfenex Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PFNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PFNX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$13.00
▲ +1.96% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Pfenex in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 1.96% upside from the last price of $12.75.

Hold

The current consensus among 4 contributing investment analysts is to hold stock in Pfenex. This rating has held steady since August 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/14/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$13.00
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/14/2020William BlairDowngradeOutperform ➝ Market Perform
i
Rating by A. Hsieh at William Blair
8/12/2020Truist FinancialDowngradeBuy ➝ Hold
i
8/11/2020JMP SecuritiesDowngradeOutperform ➝ Market Perform
i
6/15/2020OppenheimerBoost Price TargetOutperform$10.00 ➝ $15.00
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
6/1/2020OppenheimerBoost Price TargetOutperform$9.00 ➝ $10.00
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
5/12/2020SunTrust BanksLower Price TargetBuy$15.00 ➝ $13.00
i
5/10/2020OppenheimerReiterated RatingBuy$9.00
i
Rating by Esther Rajavelu at Oppenheimer Holdings Inc.
4/22/2020OppenheimerInitiated CoverageOutperform$9.00
i
2/14/2020SunTrust BanksInitiated CoverageBuy$18.00
i
12/18/2019JMP SecuritiesReiterated RatingBuy$19.00
i
Rating by Jason Butler at JMP Securities
10/24/2019Cantor FitzgeraldInitiated CoverageOverweight$20.00
i
Rating by B. Folkes at Cantor Fitzgerald
10/11/2019William BlairReiterated RatingBuy
i
9/11/2019JMP SecuritiesBoost Price TargetOutperform$13.00 ➝ $17.00
i
4/2/2019William BlairReiterated RatingBuy
i
Rating by Andy Hsieh at William Blair
3/12/2019William BlairReiterated RatingOutperform
i
3/7/2019WedbushReiterated RatingOutperform
i
9/10/2018William BlairReiterated RatingOutperform
i
8/9/2018William BlairReiterated RatingOutperform
i
4/25/2018William BlairReiterated RatingOutperform
i
3/29/2018BarclaysSet Price TargetOverweight ➝ Buy$14.00 ➝ $8.00
i
Rating by Douglas Tsao at Barclays PLC
3/16/2018William BlairReiterated RatingOutperform
i
11/10/2017JMP SecuritiesLower Price TargetPositive ➝ Outperform$21.00 ➝ $8.00
i
9/8/2017William BlairReiterated RatingOurperform
i
Rating by A. Hsieh at William Blair
8/10/2017William BlairReiterated RatingOutperform
i
Rating by A. Hsieh at William Blair
6/26/2017William BlairReiterated RatingOutperform
i
8/9/2016MizuhoLower Price TargetBuy$22.00 ➝ $18.00
i
(Data available from 6/16/2016 forward)
Pfenex logo
Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $12.75
$12.75
$12.75

50 Day Range

MA: N/A

52 Week Range

Now: $12.75
$5.26
$14.00

Volume

N/A

Average Volume

503,865 shs

Market Capitalization

$437.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Pfenex?

The following Wall Street sell-side analysts have issued stock ratings on Pfenex in the last year: Cantor Fitzgerald, JMP Securities, Truist Financial Co., William Blair, and Zacks Investment Research.
View the latest analyst ratings for PFNX.

What is the current price target for Pfenex?

1 Wall Street analysts have set twelve-month price targets for Pfenex in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 2.0%. Cantor Fitzgerald has the highest price target set, predicting PFNX will reach $13.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $13.00 for Pfenex in the next year.
View the latest price targets for PFNX.

What is the current consensus analyst rating for Pfenex?

Pfenex currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PFNX, but not buy more shares or sell existing shares.
View the latest ratings for PFNX.

What other companies compete with Pfenex?

How do I contact Pfenex's investor relations team?

Pfenex's physical mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company's listed phone number is +1-858-3524400. The official website for Pfenex is www.pfenex.com.